+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Forecast 2024-2030- Product Image
Global Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Forecast 2024-2030- Product Image
Sale

Global Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 190 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5925178
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neoantigen Cancer Vaccine Market size was estimated at USD 57.14 million in 2023, USD 60.44 million in 2024, and is expected to grow at a CAGR of 5.17% to reach USD 81.35 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neoantigen Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neoantigen Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include , Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Off-The Shell Neoantigen Vaccine
    • Personalized Neo-Antigen Vaccine
  • Technology
    • HLA Typing
    • RNA Sequencing
    • Whole Genome Sequencing
  • Delivery Mechanism
    • Electroporation
    • Gene Gun
    • Liposomes
    • Virosomes
  • Neoantigen Type
    • Dendritic Cell
    • Nucleic Acid
    • Synthetic Long Peptide
    • Tumor Cell
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Transdermal
  • Application
    • Brain Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Melanoma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Neoantigen Cancer Vaccine Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neoantigen Cancer Vaccine Market?
  3. What are the technology trends and regulatory frameworks in the Neoantigen Cancer Vaccine Market?
  4. What is the market share of the leading vendors in the Neoantigen Cancer Vaccine Market?
  5. Which modes and strategic moves are suitable for entering the Neoantigen Cancer Vaccine Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Neoantigen Cancer Vaccine Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer globally
5.1.1.2. Improvements in genomic sequencing and immunotherapy
5.1.1.3. Inclination towards early diagnosis and treatment of cancer
5.1.2. Restraints
5.1.2.1. High cost and complexity in manufacturing
5.1.3. Opportunities
5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
5.1.3.2. Emerging development of combination therapies
5.1.4. Challenges
5.1.4.1. Adverse effects and ethical issues
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Neoantigen Cancer Vaccine Market, by Product
6.1. Introduction
6.2. Off-The Shell Neoantigen Vaccine
6.3. Personalized Neo-Antigen Vaccine
7. Neoantigen Cancer Vaccine Market, by Technology
7.1. Introduction
7.2. HLA Typing
7.3. RNA Sequencing
7.4. Whole Genome Sequencing
8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism
8.1. Introduction
8.2. Electroporation
8.3. Gene Gun
8.4. Liposomes
8.5. Virosomes
9. Neoantigen Cancer Vaccine Market, by Neoantigen Type
9.1. Introduction
9.2. Dendritic Cell
9.3. Nucleic Acid
9.4. Synthetic Long Peptide
9.5. Tumor Cell
10. Neoantigen Cancer Vaccine Market, by Route of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Transdermal
11. Neoantigen Cancer Vaccine Market, by Application
11.1. Introduction
11.2. Brain Cancer
11.3. Gastrointestinal Cancer
11.4. Lung Cancer
11.5. Melanoma
12. Americas Neoantigen Cancer Vaccine Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Neoantigen Cancer Vaccine Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. "
16.1.2. "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
16.1.3. Advaxis Inc.
16.1.4. Agenus Inc.
16.1.5. AstraZeneca plc
16.1.6. Avidea Technologies
16.1.7. BioLineRx
16.1.8. BioNTech SE
16.1.9. Brightpath Biotherapeutics Co., Ltd.
16.1.10. CureVac N.V.
16.1.11. Elicio Therapeutics Inc
16.1.12. F. Hoffmann-La Roche Ltd.
16.1.13. Genocea Biosciences Inc
16.1.14. Gilead Sciences, Inc.
16.1.15. Gritstone bio, Inc.
16.1.16. Immunomic Therapeutics, Inc.
16.1.17. IMV Inc
16.1.18. ISA Pharmaceuticals BV
16.1.19. Medigene AG
16.1.20. Merck & Co., Inc.
16.1.21. Neophore Limited
16.1.22. Nouscom
16.1.23. Nykode Therapeutics ASA
16.1.24. OSE Immunotherapeutics
16.1.25. Takis srl
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
FIGURE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2030 (%)
FIGURE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2030 (%)
FIGURE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 22. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 28. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY OFF-THE SHELL NEOANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VIROSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC LONG PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 59. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 85. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 86. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 91. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 92. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 103. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 104. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 139. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 140. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 158. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 159. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 162. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 164. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 165. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 168. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 170. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 174. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 176. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 182. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 194. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 210. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 212. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 216. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 218. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 222. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 224. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 246. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 248. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 249. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 264. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 265. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 266. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 267. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 282. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 283. NEOANTIGEN CANCER VACCINE MARKET LICENSE & PRICING

Companies Mentioned

  • "
  • "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Advaxis Inc.
  • Agenus Inc.
  • AstraZeneca plc
  • Avidea Technologies
  • BioLineRx
  • BioNTech SE
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac N.V.
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences Inc
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • IMV Inc
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Neophore Limited
  • Nouscom
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis srl

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 60.44 Million
Forecasted Market Value ( USD ) by 2030 $ 81.35 Million
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031 - Product Image

Global Neoantigen Cancer Vaccine Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024 - Product Image

Neoantigen-based Personalized Cancer therapeutic Vaccines - Pipeline Insight, 2024

  • Drug Pipelines
  • 50 Pages
  • Global
From
Cancer Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Cancer Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 170 Pages
  • Global
From
Cancer Vaccines Global Market Report 2024 - Product Image

Cancer Vaccines Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030 - Product Image

Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From

About the Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine market is a subset of the larger Cancer Vaccine market. Neoantigen Cancer Vaccines are a type of personalized cancer immunotherapy that uses a patient’s own tumor-specific mutations to create a vaccine tailored to their individual cancer. These vaccines are designed to stimulate the patient’s immune system to recognize and attack cancer cells. Neoantigen Cancer Vaccines are still in the early stages of development, but have shown promise in clinical trials. The Neoantigen Cancer Vaccine market is expected to grow as more personalized cancer treatments become available. Companies in the market include Moderna, BioNTech, CureVac, and Inovio Pharmaceuticals. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.